[{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sernova \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Sernova \/ AstraZeneca"},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Evotec"},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Evotec"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Thyroid Cell","moa":"T3\/T4","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sernova \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sernova

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Company’s Cell Pouch auto-transplanted with thyroid cells is being investigated for nodular thyroid disease. It restores thyroxine and triiodothyronine, to pre-thyroidectomy levels.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 03, 2025

                          Lead Product(s) : Thyroid Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Sernova’s Cell Pouch System™ (human donor islets cell) is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells.

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          October 01, 2023

                          Lead Product(s) : Human Donor Islet Cell,Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Evotec

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Sernova’s Cell Pouch System™ (human donor islets cell) is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells.

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 03, 2023

                          Lead Product(s) : Human Donor Islet Cell,Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the collaboration, AstraZeneca will explore the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Sernova’s Cell Pouch System is a novel implant consisting human islets cells, which allows for reestablishment of production of triiodothyronine (T3) and thyroxine (T4) and the hypothalamic-pituitary-thyroid axis, to preserve thyroid function following...

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 30, 2023

                          Lead Product(s) : Human Donor Islet Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Human Donor Islets Cell are transplanted into the Sernova Cell Pouch approximately six weeks after Cell Pouch implantation to allow development of fully vascularized native tissue chambers and achieve a stable immunosuppressant regimen.

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 17, 2022

                          Lead Product(s) : Human Donor Islet Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The Cell Pouch is implantable device, that is transplanted with therapeutic cells such as Sernova Cell Pouch (insulin producing islets). Combination product is designed for treatment of Type 1 Diabetes Mellitus with hypoglycemia.

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 11, 2022

                          Lead Product(s) : Human Donor Islet Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Sernova will use the net proceeds from the common shares for general working capital purposes and to continue pursuing ‘functional cures’ for diabetes, hypothyroidism and hemophilia A by using Human donor islets cell (Sernova Cell Pouch).

                          Product Name : Sernova Cell Pouch

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 09, 2022

                          Lead Product(s) : Human Donor Islet Cell,Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Evotec

                          Deal Size : $270.0 million

                          Deal Type : Financing

                          blank